Mylotarg (Gemtuzumab Ozogamicin) Injection, Wyeth-Ayerst NDA 21-174/S-002 2/23/01 4/23/03 Mylotarg (Gemtuzumab Ozogamicin) Injection, Wyeth-Ayerst NDA 21-174 5/17/00 5/22/00 5/22/00 6/4/01 Mylotarg Indication: for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy. Mylotarg (Gemtuzumab Ozogamicin) Injection, Wyeth Pharmaceuticals Mylotarg (gemtuzumab ozogamicin) for Injection, Wyeth Pharmaceuticals 21-174/S-012,-014 Mylotarg (gemtuzumab ozogamicin) for Injection, Wyeth Pharmaceuticals, Package Change

For the most up-to-date approval information, please locate this API using the drug index.